Cargando…

The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review

Background: Carcinomas of unknown primary (CUP) account for 3–5% of all malignancy and, despite a reduction in incidence, the overall survival has not improved over the last decade. Chemotherapy regimens have not provided encouraging results. New diagnostic technologies, such as next generation sequ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lombardo, Roberta, Tosi, Federica, Nocerino, Annunziata, Bencardino, Katia, Gambi, Valentina, Ricotta, Riccardo, Spina, Francesco, Siena, Salvatore, Sartore-Bianchi, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225282/ https://www.ncbi.nlm.nih.gov/pubmed/32457826 http://dx.doi.org/10.3389/fonc.2020.00533

Ejemplares similares

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA
por: Patelli, Giorgio, et al.
Publicado: (2021)

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
por: Amatu, A, et al.
Publicado: (2019)

Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study
por: Amatu, Alessio, et al.
Publicado: (2022)

Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2023)

Chemotherapy-induced myasthenic crisis in thymoma treated with primary chemotherapy with curative intent on mechanical ventilation: a case report and review of the literature
por: Patelli, Giorgio, et al.
Publicado: (2021)

Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
por: Patelli, Giorgio, et al.
Publicado: (2023)

Unknown unknowns: essential genes in quest for function
por: Danchin, Antoine, et al.
Publicado: (2016)

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
por: Amatu, Alessio, et al.
Publicado: (2016)

Labeling Pathological Tau: An Important Quest for the Unknown
por: Vega, Irving E.
Publicado: (2016)

Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2017)

Liquid biopsies to monitor and direct cancer treatment in colorectal cancer
por: Mauri, Gianluca, et al.
Publicado: (2022)

The big questions in science: the quest to solve the great unknowns
por: Birch, Hayley, et al.
Publicado: (2016)

Gold and silver dichroic nanocomposite in the quest for 3D printing the Lycurgus cup
por: Kool, Lars, et al.
Publicado: (2020)

Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP
por: Folprecht, Gunnar, et al.
Publicado: (2020)

Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the ‘U’ out of ‘CUP’
por: Conway, Alicia-Marie, et al.
Publicado: (2018)

Phase II Open-Label Study to Assess Efficacy and Safety of Lenalidomide in Combination with Cetuximab in KRAS-Mutant Metastatic Colorectal Cancer
por: Siena, Salvatore, et al.
Publicado: (2013)

Hijama (Wet Cupping or Dry Cupping) for Diabetes Treatment
por: Vakilinia, Seyed Reza, et al.
Publicado: (2016)

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
por: Roncato, Rossana, et al.
Publicado: (2020)

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
por: Siena, Salvatore, et al.
Publicado: (2009)

Germline genetics of cancer of unknown primary (CUP) and its specific subtypes
por: Hemminki, Kari, et al.
Publicado: (2016)

Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP)
por: Es, Hamidreza Aboulkheyr, et al.
Publicado: (2021)

Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review
por: Gazzaniga, Gianluca, et al.
Publicado: (2022)

A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS).
por: Warner, E., et al.
Publicado: (1998)

Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment
por: Amatu, Alessio, et al.
Publicado: (2022)

Early‐onset colorectal cancer in young individuals
por: Mauri, Gianluca, et al.
Publicado: (2018)

Insights from the genetic and transcriptional characterization of a cancer of unknown primary (CUP)
por: Davalos, Veronica, et al.
Publicado: (2020)

Mitochondrial Manipulation and the Quest for Alzheimer's Treatments
por: Swerdlow, Russell H.
Publicado: (2015)

Chordoma: The Quest for Better Treatment Options
por: Heery, Christopher R.
Publicado: (2016)

Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management
por: Vallerio, P., et al.
Publicado: (2021)

Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary)
por: Lequin, Delphine, et al.
Publicado: (2007)

Cancer of unknown primary (CUP) presenting as a Spigelian hernia: a case report
por: Carollo, Andrea, et al.
Publicado: (2017)

Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?
por: Bochtler, Tilmann, et al.
Publicado: (2019)

Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
por: Amodio, Vito, et al.
Publicado: (2021)

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2020)

RoboCUP 2014
por: Bianchi, Reinaldo A C, et al.
Publicado: (2015)

Carcinoma of Unknown Primary (CUP) versus CUP Turned to Primary Carcinoma of the Head and Neck—An Analysis of Diagnostic Methods and the Impact of Primary Tumor on Clinical Outcome
por: Faisal, Muhammad, et al.
Publicado: (2022)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
por: Amatu, Alessio, et al.
Publicado: (2019)

Survival Outcome in True Carcinoma of Unknown Primary (tCUP) with p16 + Cervical Metastasis
por: Faisal, Muhammad, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ohoi70fcebo0n5ub0j33c1pd86